Mohsen Nakhaie

Dr. Mohsen Nakhaie


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
JCJavad Charostad
Javad Charostad
MRMohammad Rezaei Zadeh Rukerd
Mohammad Rezaei Zadeh Rukerd
SMShahab Mahmoudvand
Shahab Mahmoudvand
DBDavood Bashash
Davood Bashash
SHSeyed Mohammad Ali Hashemi
Seyed Mohammad Ali Hashemi
KZKeivan Zandi
Keivan Zandi
Avian influenza viruses (AIVs) are globally challenging due to widespread circulation and high mortality rates. Highly pathogenic avian influenza (HPAI) strains like H5N1 have caused significant outbreaks in birds. Since 2003 to 14 July 2023, the World Health Organization (WHO) has documented 878 cases of HPAI H5N1 infection in humans and 458 (52.16%) fatalities in 23 countries. Recent outbreaks in wild birds, domestic birds, sea lions, minks, and etc., and the occurrence of genetic variations among HPAI H5N1 strains raise concerns about potential transmission and public health risks. This paper aims to provide a comprehensive overview of the current understanding and new insights into HPAI H5N1. It begins with an introduction to the significance of studying this virus and highlighting the need for updated knowledge. The origin and evaluation of HPAI H5N1 are examined, shedding light on its emergence, and spread across different geographic regions. The genome organization and structural biology of the H5N1 virus are explored, providing insights into its molecular composition and key structural features. This manuscript also delves into the phylogeny, evolution, mutational trends, reservoirs, and transmission routes of HPAI H5N1. The immune response against HPAI H5N1 and its implications for vaccine development are analyzed, along with an exploration of the pathogenesis and clinical manifestations of HPAI H5N1 in human cases. Furthermore, diagnostic tools and preventive and therapeutic strategies are discussed, highlighting the current approaches and potential future directions for better management of the potential pandemic.

4 November 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
MNMohsen Nakhaie
Mohsen Nakhaie
NANasir Arefinia
Nasir Arefinia
JCJavad Charostad
Javad Charostad
DBDavood Bashash
Davood Bashash
MAMohadeseh Haji Abdolvahab
Mohadeseh Haji Abdolvahab
MZMohammad Zarei
Mohammad Zarei

26 February 2023 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
VSVahideh Hamidi Sofiani
Vahideh Hamidi Sofiani
PVParsa Veisi
Parsa Veisi
MRMohammad Rezaei Zadeh Rukerd
Mohammad Rezaei Zadeh Rukerd
RGReza Ghazi
Reza Ghazi
MNMohsen Nakhaie
Mohsen Nakhaie
Among human tumorigenic viruses, the role of Human papillomavirus (HPV) has been proven as one of the most important oncoviruses that are associated with a large number of cancers. Most cancers of the genital area such cervical and anal cancer as are caused by HPV, and in many other cancers, such as colorectal, gastric, liver, esophageal, urinary bladder, and head and neck cancers, it is considered as one of the important risk factors. Our search was conducted for published researches between 2000 and 2022 by using several international databases including Scopus, PubMed, and Web of Science as well as Google scholar. We also evaluated additional evidence from relevant published articles. It has been demonstrated that HPV can promote tumorigenesis via focusing on genes, proteins, and signaling pathways, by using E6 and E7 oncoproteins and inhibiting two crucial tumor suppressors, P53 and Rb. The following study was performed to investigate different malignant cancers under the influence of HPV infection and changes in molecular factors caused by HPV infection.

16 April 2022 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
VHVahideh Hamidi-Sofiani
Vahideh Hamidi-Sofiani
RRReza Rakhshi
Reza Rakhshi
NMNiloufar Moradi
Niloufar Moradi
PZParisa Zeynali
Parisa Zeynali
MNMohsen Nakhaie
Mohsen Nakhaie
EBEmad Behboudi
Emad Behboudi
Today, the pancreatic cancer prognosis is poor and genetic technology is developing to treat various types of cancers. Scientists are actively looking for a new technique to design a therapeutic strategy to treat pancreatic cancer. Several oncolytic viruses are known to be valuable tools for pancreatic cancer treatment. Recent Studies demonstrate their effectiveness and safety in various administration routes such as direct intratumoral, intracutaneous, intravascular, and other routes. In this study, all studies conducted in the past 20 years have been reviewed. Reputable scientific databases including Irandoc, Scopus, Google Scholar and PubMed, are searched for the keywords of Pancreatic cancer, oncolytic, viruses and treatment and the latest information about them is obtained. Engineering the oncolytic viruses' genome and insertion of intended transgenes including cytokines or shRNAs, has caused promising promotions in pancreatic cancer treatment. Some oncolytic viruses inhibit tumors directly and some through activation of immune responses. This approach showed some signs of success in efficiency like immune system activation in the tumor environment, effective virus targeting in the tumor cells by systemic administration, and enhanced patient survival in comparison with the control group. But of course, until now, using these oncolytic viruses alone has not been effective in elimination of tumors.

1 September 2021 in New Microbes and New Infections
Verified
Journal Article
Open access
EBEmad Behboudi
Emad Behboudi
VHV. Hamidi
V. Hamidi
FGF. Gholizadeh
F. Gholizadeh
EGE.M. Grala
E.M. Grala
YGY. Ghelmani
Y. Ghelmani
AAA. Astani
A. Astani
Blood group antigens are one of the most important antigens in humans that have an impact on susceptibility to disease and may be used as a prognosis factor in different diseases such as COVID-19. The study aimed to investigate the relationship between ABO blood groups and Rhesus antigen and susceptibility to COVID-19. The clinical data of 398 subjects were used in the investigation collected from 148 cases vs. 250 controls. This information was obtained from Shahid Sadoughi Hospital of Yazd (IRAN) University. Blood groups and outcomes were assessed using statistical tests for four populations: COV + vs. COV− and COV +/deceased vs. COV +/live. Out of a total of 148 COVID-19 patients, 80 (54/1%) were male, 68 (45/9%) were female. Among these patients, 33 (22/6%) had type A+, 44 (30/1%) had type B+, 13 (8/9%) had type AB+, and 36 (24/7%) had type O+. On the other hand, out of 148 patients, 126 (86/3%) had positive blood types, and 20 (13/7%) had negative blood types. As a result, no significant difference was found in the relationship between ABO blood groups and RH type and susceptibility to COVID-19 (p-value = 0.392 and p-value = 0.847, respectively). Other data showed a significant difference between patients group with other parameters such as age (p-value<0.001) and gender (p-value<0.001). Although in this study there was no association between blood type and RH type with COVID-19, findings of the association between age and gender can confirm the results of previous studies.

25 August 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJavad Charostad
Javad Charostad
MRMohammad Rezaei Zadeh Rukerd
Mohammad Rezaei Zadeh Rukerd
ASAzadeh Shahrokhi
Azadeh Shahrokhi
FAFaezeh Afkhami Aghda
Faezeh Afkhami Aghda
YGYaser Ghelmani
Yaser Ghelmani
EKEhsan Kakavand
Ehsan Kakavand
Background: The occurrence of variations in routine hematological parameters is closely associated with disease progression, the development of severe illness, and the mortality rate among COVID-19 patients. This study aimed to investigate hematological parameters in COVID-19 hospitalized patients from the 1st to the 5th waves of the current pandemic. Methods: This cross-sectional study included a total of 1501 hospitalized patients with laboratory-confirmed COVID-19 based on WHO criteria, who were admitted to Shahid Sadoughi Hospital (SSH) in Yazd, Iran, from February 2020 to September 2021. Throughout, we encountered five COVID-19 surge waves. In each wave, we randomly selected approximately 300 patients and categorized them based on infection severity during their hospitalization, including partial recovery, full recovery, and death. Finally, hematological parameters were compared based on age, gender, pandemic waves, and outcomes using the Mann-Whitney U and Kruskal-Wallis tests. Results: The mean age of patients (n = 1501) was 61.1±21.88, with 816 (54.3%) of them being men. The highest mortality in this study was related to the third wave of COVID-19 with 21.3%. There was a significant difference in all of the hematological parameters, except PDW, PLT, and RDW-CV, among pandemic waves of COVID-19 in our population. The highest rise in the levels of MCV and RDW-CV occurred in the 1st wave, in the 2nd wave for lymphocyte count, MCHC, PLT count, and RDW-SD, in the 3rd wave for WBC, RBC, neutrophil count, MCH, and PDW, and in the 4th wave for Hb, Hct, and ESR (p < 0.01). The median level of Hct, Hb, RBC, and ESR parameters were significantly higher, while the mean level of lymphocyte and were lower in men than in women (p < 0.001). Also, the mean neutrophil in deceased patients significantly was higher than in those with full recovered or partial recovery (p < 0.001). Conclusion: The findings of our study unveiled notable variations in hematological parameters across different pandemic waves, gender, and clinical outcomes. These findings indicate that the behavior of different strains of the COVID-19 may differ across various stages of the pandemic.